If you or a loved one are living with scleroderma, consider joining a scleroderma clinical study where researchers are evaluating the potential effect of a new study drug on disease activity and disease progression in individuals with scleroderma.
The purpose of this study is to evaluate the effect of tibulizumab on skin thickening, lung thickening, and function.
You may be eligible to participate in this study if you:
By enrolling in this Phase 2 study, you may receive:
Travel and accommodation support for study visits
Study-related healthcare at no cost
Insurance is not required to join this study
By enrolling in this study, you may participate in a clinical study working to evaluate the effect of a study drug on disease activity and progression in the skin and lungs.
Your participation may support the advancement of a study drug for individuals with scleroderma.
Click the "I'm Interested" and enter your information to express interest in the study. You can also email studies@patientwing.com or call 213-459-2979.
If you qualify for the study and choose to participate, you will have visits to the research site every 4 weeks, with the exception of a visit 2 weeks after the first dose and the final visit being 12 weeks after the last dose, for a total of 16 visits.
If you qualify for the study and choose to participate, there is no cost to participate in this clinical study. The study sponsor will pay for the costs of the study drug and any study-required tests or procedures. You can talk to the research site staff about your eligibility for assistance with travel and accommodation support for study visits.
If you qualify for the study and choose to participate, you will be given an injection under the skin (subcutaneous injection) every two weeks for the first month and then every four weeks after.
The study takes about 1 year and 3 months from the start of the screening activities to the follow-up visit.
By participating in this study, you can contribute to a better understanding of scleroderma. The data obtained from you during this study may help doctors learn more about the potential effects of tibulizumab in patients with scleroderma.
